An anti-interleukin-1 (anti-IL-1) alpha antibody called MABp1 has been shown to significantly improve response in patients with metastatic colorectal cancer (mCRC) in a phase III clinical trial that adopted symptom control as criteria for objective response (OR).
Regorafenib significantly improves overall survival (OS) and progression-free survival (PFS) in patients with intermediate or advanced hepatocellular carcinoma (HCC) whose disease progressed on sorafenib treatment, according to results of the phase III RESOURCE trial presented at the European Society for Medical Oncology (ESMO) 18th World Congress on Gastrointestinal Cancer.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).